Search Results

You are looking at 1 - 10 of 30 items for :

  • "Glucocorticoid replacement" x
  • All content x
Clear All
Open access

David J F Smith, Hemanth Prabhudev, Sirazum Choudhury, and Karim Meeran

mineralocorticoid production in primary adrenal failure. The mainstay of treatment is glucocorticoid replacement, with either hydrocortisone or prednisolone ( 2 ). Both work by binding to the glucocorticoid receptor (GR) for which prednisolone has the greater

Open access

Sirazum Choudhury, Tricia Tan, Katharine Lazarus, and Karim Meeran

Introduction Between 1928 and 1938, patients with Addison’s disease had a 100% 5-year mortality ( 1 ). With the availability of glucocorticoid replacement therapy, initially with animal adrenocortical extract and later synthetic 11

Open access

Salem A Beshyah, Khawla F Ali, and Hussein F Saadi

therapy? (Once daily (full dose), Twice daily, Three times daily, Four times daily).  5. How do you perceive the impact of Ramadan fasting (RF) on adrenal insufficiency and its management (There is no concern on glucocorticoid replacement therapy

Open access

Marcus Quinkler, Bertil Ekman, Claudio Marelli, Sharif Uddin, Pierre Zelissen, Robert D Murray, and on behalf of the EU-AIR Investigators

glucocorticoid replacement therapies ( 21 ). The primary objective of the EU-AIR is to monitor the safety of long-term treatment with once-daily modified-release hydrocortisone and other glucocorticoid replacement therapies in patients with AI. All enrolled

Open access

Stephanie Burger-Stritt, Linda Bachmann, Max Kurlbaum, and Stefanie Hahner

outcomes with current glucocorticoid replacement therapy . Clinical Endocrinology 2015 82 2 – 11 . ( https://doi.org/10.1111/cen.12603 ) 10.1111/cen.12603 25187037 25 Jenkins JS Sampson PA . Conversion of cortisone to cortisol and prednisone to

Open access

Lia Ferreira, João Silva, Susana Garrido, Carlos Bello, Diana Oliveira, Hélder Simões, Isabel Paiva, Joana Guimarães, Marta Ferreira, Teresa Pereira, Rita Bettencourt-Silva, Ana Filipa Martins, Tiago Silva, Vera Fernandes, Maria Lopes Pereira, and Adrenal Tumors Study Group of the Portuguese Society of Endocrinology

glucocorticoids in patients with AD. Furthermore, symptoms and electrolyte disturbances at the last appointment were evaluated. A comparative analysis was performed to investigate the type of glucocorticoid replacement and aetiology, mean daily hydrocortisone

Open access

Kathrin R Frey, Tina Kienitz, Julia Schulz, Manfred Ventz, Kathrin Zopf, and Marcus Quinkler

frequency of fractures ( P  = 0.144). Table 3 Clinical data, concomitant medications and fractures in patients with adrenal insufficiency separated into different glucocorticoid replacement groups during study period 2010–2017. Immediate

Open access

L M Mongioì, R A Condorelli, S La Vignera, and A E Calogero

LT4 50 µg/dayTestosterone enanthate 250 mg every 4 weeks 22 9 F 45 Hypopituitarism Hypothyroidism, hypogonadism, obesity None LT4 75 µg/die 7 Among these patients, 14 were already on glucocorticoid replacement therapy

Open access

Thabiso R P Mofokeng, Salem A Beshyah, Fazleh Mahomed, Kwazi C Z Ndlovu, and Ian L Ross

-Saharan Africa. Patient management trends The proportion of patients using hydrocortisone alone in the MENA region was 34% (780/828), compared to 28% (588/1474); P  < 0.001) in SSA. Several formulations of glucocorticoid replacement therapy were

Open access

V Guarnotta, C Di Stefano, A Santoro, A Ciresi, A Coppola, and C Giordano

the authors. References 1 Johannsson G Falorni A Skrtic S Lennernäs H Quinkler M Monson JP Stewart PM . Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy . Clinical